Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Wednesday, July 26, 2017
 
Recommended for you
Democrats Announce Three-Pronged Plan To Tackle High Drug Prices
Kaiser Health News
Galmed Pharmaceuticals: Buy On Weakness
Seeking Alpha • Jonathan Faison
Biotech Forum Daily Digest: Sector Meanders In Front Of Earnings
Seeking Alpha • Bret Jensen
The Tasmanian Hep C Buyers’ Club
The New York Times • Sophie Cousins
Recent Buy: Gilead Sciences
Seeking Alpha • Fiscal Voyage
Gilead Sciences says late-stage results for HIV drug combination are similar to standard of care
MarketWatch • Emmacourt, Reporter
HIV fight advances with new drug cocktails, fresh vaccine hopes
Reuters
The Trump Rally Has Been Good: This Approach Is Better
Seeking Alpha • Tdp Research
Stocks to watch next week
Seeking Alpha • Jason Aycock
Gilead Has Another Ace Up Its Sleeve
Seeking Alpha • Long Term Bio
 
Recommended for You
Gilead Sciences, GlaxoSmithKline plc
Democrats Announce Three-Pronged Plan To Tackle High Drug Prices
Kaiser Health News
News outlets report on stories related to pharmaceutical pricing. Politico: Democrats' 'Better Deal' Would Penalize Drug Price Hikes Democrats are going straight at one of the top concerns of voters, using the rising cost of drugs to strike a more populist tone...
Share
Gilead Sciences, Health Finance
Galmed Pharmaceuticals: Buy On Weakness
Seeking AlphaJonathan Faison
Summary Shares have risen over 80% since initially bringing the stock to readers' attention. Data presented at EASL continued to indicate the significant potential of Aramchol in the NASH setting. Intriguing implications are discussed considering the appointment of Dr. Carol Brosgart to...
Share
Gilead Sciences, Health Finance
Biotech Forum Daily Digest: Sector Meanders In Front Of Earnings
Seeking AlphaBret Jensen
Summary The biotech sector has meandered in trading so far this week in front of expected second quarter results from biotech stalwarts like Gilead Sciences. CymaBay Therapeutics continues to be a monster stock so far in 2017. Some good news for Reata...
Share
Cancer, Gilead Sciences
The Tasmanian Hep C Buyers’ Club
The New York TimesSophie Cousins
CHENNAI, India — In 2014, when Greg Jefferys’s urine started smelling like dead meat, he knew there was something seriously wrong. For weeks, Jefferys, an Australian then 60 years old, had felt fatigued and noticed that just a slight bump would leave...
Share
Gilead Sciences, Health Finance
Recent Buy: Gilead Sciences
Seeking AlphaFiscal Voyage
Summary History and current state. What is GILD's fair price? What I did, and what I continue to do. So far this month I have made three stock purchases. I previously wrote analyses on my first two purchases. Today I am going...
Share
Finance, Gilead Sciences
Gilead Sciences says late-stage results for HIV drug combination are similar to standard of care
MarketWatchEmmacourt, Reporter
Gilead Sciences Inc. said early Monday that its HIV combination treatment had similar safety and efficacy results in two late-stage clinical trials to the standard of care. The data, along with two other late-stage clinical trials, are the basis of Gilead's U.S....
Share
Gilead Sciences, GlaxoSmithKline plc
HIV fight advances with new drug cocktails, fresh vaccine hopes
Reuters
LONDON (Reuters) - Three decades after approval of the first-ever AIDS treatment, HIV medicine is seeing a new wave of innovation with scientists reporting positive data on Monday for improved drug cocktails and a novel experimental vaccine.
Share
Gilead Sciences
The Trump Rally Has Been Good: This Approach Is Better
Seeking AlphaTdp Research
Summary The "Trump Rally" has created profits for many investors. The president claims it has created $4 trillion in new wealth. The key to beating the market is finding a few companies that are better buying opportunities than the index. I show...
Share
Charter Communications, Federal Reserve
Stocks to watch next week
Seeking AlphaJason Aycock
Key events are scheduled for the companies listed below next week. Fed watch: The Fed Open Market Committee meets Tuesday and Wednesday, July 25 and 26, and will produce a monetary policy statement at 2 p.m. on July 26. Notable earnings reports:...
Share
Gilead Sciences, Health Finance
Gilead Has Another Ace Up Its Sleeve
Seeking AlphaLong Term Bio
Summary Approval of Vosevi should help the company produce more sales in Hep C space. Two phase 3 studies show that Vosevi can be a contender. Combination drug from another company looks to steal market share. Recently, Gilead Sciences (GILD) announced it...
Share